Follow
Nikta Shobeiri
Nikta Shobeiri
Assistant Professor, School of Pharmacy, Mashhad University of Medical Sciences
Verified email at mums.ac.ir
Title
Cited by
Cited by
Year
Synthesis and biological evaluation of quinoline analogues of flavones as potential anticancer agents and tubulin polymerization inhibitors
N Shobeiri, M Rashedi, F Mosaffa, A Zarghi, M Ghandadi, A Ghasemi, ...
European journal of medicinal chemistry 114, 14-23, 2016
1042016
Country pharmaceutical situation on access, quality, and rational use of medicines: An evidence from a middle-income country
H Minaei, M Peikanpour, N Yousefi, P Peymani, F Peiravian, N Shobeiri, ...
Iranian Journal of Pharmaceutical Research: IJPR 18 (4), 2191, 2019
102019
Evaluating the affordability of asthma, chronic obstructive pulmonary disease, and cystic fibrosis medicines in a middle-income country
M Fathi, N Moradi, N Yousefi, F Peiravian, N Shobeiri
BMC Pulmonary Medicine 23 (1), 429, 2023
2023
How Do Iranian Stakeholders Think About Pharmaceutical Managed Entry Agreements?
N Shobeiri, F Peiravian, N Yousefi
Iranian Journal of Pharmaceutical Research: IJPR 21 (1), 2022
2022
PCN23 Cost-Effectiveness Analysis of Topotecan, Pegylated Liposomal Doxorubicin Hydrochloride, and paclitaxel As Second-LINE Chemotherapy in the Treatment of Platinum-Resistant …
N Shobeiri
Value in Health Regional Issues 22, S8, 2020
2020
COST-EFFECTIVENESS ANALYSIS OF TOPOTECAN IN COMPARISON WITH PACLITAXEL AS SECOND-LINE CHEMOTHERAPY IN THE TREATMENT OF PLATINUM-RESISTANT OVARIAN CANCER IN IRAN
N Shobeiri, S Taheri, S Sheikhi, F Peiravian
ISPOR Europe 2019, 2019
2019
PCN212 ECONOMIC EVALUATION OF TOPOTECAN IN COMPARISON WITH PEGYLATED LIPOSOMAL DOXORUBICIN IN THE TREATMENT OF RECURRENT OVARIAN CANCER IN IRAN
S Sheikhi, S Taheri, N Shobeiri, F Peiravian
Value in Health 22, S477, 2019
2019
The system can't perform the operation now. Try again later.
Articles 1–7